Obinutuzumab plus chemotherapy for certain CD20+ relapsed lymphomas
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This Phase 2 study tests how well obinutuzumab (an antibody medicine) combined with chemotherapy works for people whose CD20-positive B-cell lymphoma has come back or didn’t respond to initial treatment. It may help by attacking lymphoma cells that carry the CD20 marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CD20-positive B-cell lymphoma that is either in first relapse or didn’t respond to initial treatment
- Your type fits one of these: diffuse large B-cell lymphoma, Burkitt lymphoma, high-grade B-cell lymphoma (NOS), primary mediastinal B-cell lymphoma, CD20+ B-lymphoblastic lymphoma, or follicular lymphoma grade 3
- You have had no obinutuzumab before (GA101)
- Your last chemotherapy was at least 2 weeks ago (no recent chemo that lowers blood counts)
- If you had radiation before: small local palliative radiation must be over 2 weeks ago; larger/brain/spine/pelvis radiation must be over 6 months ago (or over 6 weeks for other bigger marrow radiation)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a maintenance drug called obinutuzumab can help prevent relapse in people with primary central nervous system lymphoma (a rare lymphoma in the brain or spine) who have already responded to initial chemotherapy. It is for those who have achieved at least a partial or complete response to their first treatment.
This trial tests a combination of two medications (obinutuzumab and CC-99282) for people with a type of lymphoma called follicular lymphoma that has not been treated before and is considered high-burden (meaning it is widespread or growing quickly). The goal is to see if this combination helps control the cancer.
This study looks at giving obinutuzumab together with lenalidomide to adults whose follicular lymphoma has come back or did not respond well to prior treatment. It may help control the cancer after relapse or resistance to standard therapies.
This real-world study looks at how well obinutuzumab-based treatment works for people with newly diagnosed follicular lymphoma. It is meant for patients whose cancer is measurable on scans and who are eligible for specific standard treatment combinations.
This trial studies whether obinutuzumab combined with lenalidomide can control marginal zone lymphoma that has come back or not responded to prior treatment. If you qualify, you may receive these medicines together to help shrink tumors and improve symptoms.
This trial tests glofitamab alone or with chemotherapy and immunotherapy in children and young adults whose “mature B-cell” non-Hodgkin lymphoma has come back or hasn’t responded to treatment. It looks at whether the study medicines can shrink lymphoma again and are safe enough to use in this age group.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.